$CYTR News,,, CytRx to Present Global Phase 3

New Post Public Reply Private Reply Replies (0) Message Board
fitzkarz
283
$CYTR News,,,

CytRx to Present Global Phase 3 Aldoxorubicin Clinical Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual Meeting
14 hours 40 minutes ago - DJNF
Oral Presentation Highlighting Updated and More Detailed Results from Global Phase 3 Trial in STS

LOS ANGELES, May 17, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the presentation of two abstracts at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2017 in Chicago. The first is an oral presentation featuring updated and more detailed results from the Company's global Phase 3 clinical trial evaluating aldoxorubicin versus investigator's choice in patients with relapsed and refractory soft tissue sarcomas (STS). The other is a poster presentation describing updated data from an ongoing Phase 1/2 clinical trial combining aldoxorubicin with ifosfamide/mesna (I-M) in first- and second-line STS.

"In addition to the significantly prolonged progression-free survival achieved by both North American and L-sarcoma patients, the data presented at ASCO this year demonstrate that, unlike any other drugs in this class, aldoxorubicin can be dosed continuously with minimal to no cardiotoxicity," commented Sant Chawla, M.D., F.R.A.C.P., Director of the Sarcoma Oncology Center in Santa Monica, California, and Principal Investigator for the Phase 3 trial. "Another distinct advantage is its ability to be administered to patients who have already been treated with doxorubicin. Taken together, these findings support aldoxorubicin's potential as a superior anthracycline treatment for patients suffering with these highly complex and difficult to treat types of cancer."

Daniel Levitt, M.D., Ph.D., Chief Operating Officer and Chief Medical Officer of CytRx, commented, "The data from both of these important clinical trials evaluating aldoxorubicin in sarcomas, along with our several other completed clinical and preclinical studies, will form the basis of our planned New Drug Application submission to the U.S. Food and Drug Administration, and we are pleased to share these more mature and detailed results in this peer-reviewed forum with the medical and scientific communities."

Details for the presentations at ASCO 2017:

Oral Presentation

Title: Phase III study of aldoxorubicin vs investigators' choice as treatment for relapsed/refractory soft tissue sarcomas

Presenter: Sant Chawla, M.D., F.R.A.C.P., Director of the Sarcoma Oncology Center in Santa Monica, and Principal Investigator

Abstract #: 11000

Session Title: Oral Abstract Session: Sarcoma

Location: S100bc

Date and Time: Friday, June 2, 2017; 3:00pm-6:00pm CT

Summary: This multicenter, randomized, open-label Phase 3 trial enrolled 433 patients at 79 sites. The data summarized here are as of August 2016. In patients with leiomyosarcoma and liposarcoma (n=246), aldoxorubicin demonstrated median progression-free survival (PFS) of 5.32 months, compared to a median PFS of 2.96 months for investigator's choice therapy, a statistically significant improvement of 2.36 months (p=0.007; hazard ratio (HR)=0.62, 95% CI 0.44-0.88), representing a 38% reduction in the risk of tumor progression. In patients treated in North America plus Australia (n=312), aldoxorubicin demonstrated a median PFS of 4.21 months, compared to a median PFS of 2.96 months for investigator's choice therapy, a statistically significant improvement of 1.25 months (p=0.023, HR=0.71, 95% CI 0.53-0.96). In the overall intent to treat (ITT) trial population (n=433), aldoxorubicin performed better than investigator's choice demonstrating a median PFS of 4.11 months, compared to a median PFS of 2.96 months for investigator's choice therapy, narrowly missing statistical significance (p=0.087; HR=0.81, 95% CI 0.64-1.03). All responses in this study were determined by an independent, blinded central lab assessment of scans.

Key safety findings included that aldoxorubicin caused no clinically significant cardiac, renal, or hepatic toxicities. Aldoxorubicin administered at 350mg/m(2) per cycle showed no cardiotoxicity up to 40 cycles. Importantly, left ventricular ejection fraction (LVEF) below 50% of expected values were reported in 4.2% of patients treated with aldoxorubicin, compared to 19.1% for patients receiving investigator's choice. Additionally, >=20% decreases in LVEF from baseline were reported in 3.8% of patients treated with aldoxorubicin, compared to 8.5% for patients receiving investigator's choice. For the global trial population, the most commonly reported (>=10%) Grade >=3 adverse events were neutropenia, anemia, febrile neutropenia, stomatitis and decreased white blood cell count, and were manageable with standard supportive care. The non-cardiac Grade >=3 adverse events associated with aldoxorubicin were similar to doxorubicin despite exposure up to 3-4 times the standard doxorubicin dose.

Updated data relating to the trials other secondary endpoints, including objective response rate (ORR), disease control rate (DCR), overall survival, and other safety parameters were in line with what has previously been reported by CytRx and will be included in the oral presentation being given at ASCO 2017.

Following conclusion of Dr. Chawla's presentation, a PDF copy of the oral presentation slides will be available at http://cytrx.com/investors/presentations.

Poster Presentation

Title: Administration of aldoxorubicin and 14 days continuous infusion of ifosfamide/Mesna in metastatic or locally advanced sarcomas

Presenter: Frederick C. Eilber, M.D., Director of the UCLA Sarcoma Translational Research Program within the Jonsson Comprehensive Cancer Center

Abstract #: 11051

Session Title: Poster Session: Sarcoma

Location: Hall A

Poster board#: 374

Date and Time: Sunday, June 4, 2017; 8:00am-11:30am CT

Summary: This ongoing open-label Phase 1/2 clinical trial is designed to assess the preliminary safety and activity of aldoxorubicin plus I-M as a first- or second-line treatment in patients with STS. Patients were administered 1 of 2 dose levels of aldoxorubicin (170mg/m(2) or 250mg/m(2) [125mg/m(2) or 185mg/m(2) doxorubicin equivalent]) on Day 1, then I-M (1g/m(2) of each per day) was administered for up to 14 days as a continuous infusion. Chemotherapy cycles were repeated at 28 day intervals, but I-M was limited to a maximum of 6 cycles to avoid cumulative bone marrow toxicity. Aldoxorubicin was continued per investigator decision in either responding or stable disease (SD) patients. Patients were followed for tumor response by CT scans and echocardiogram for cardiac toxicity every 8 weeks along with standard labs.

Of the 44 evaluable patients as of May 10, 2017, 16 patients (36%) achieved a partial response (PR), 25 patients (57%) achieved SD, with 20 patients (45%) achieving SD for >=4 months, for an overall disease control rate (DCR) of 82% (PR+SD>=4). Twenty-two of 44 (50%) patients received at least 6 cycles of aldoxorubicin (>1,300 mg/m(2) cumulative doxorubicin equivalent). As of the data cutoff date, the median PFS had not been reached. The most commonly reported Grade >=3 adverse event (AEs; >20%) were neutropenia and anemia. Reported serious adverse events (SAEs) included febrile neutropenia (14%, n=6), anemia (5%, n=2), thrombocytopenia (2%, n=1), stomatitis (2%, n=1) and pyrexia (2%, n=1). No clinically significant cardiotoxicity has been observed and no patients had a clinically significant decrease in LVEF or QTc prolongation, despite administration of median cumulative doses of doxorubicin equivalents of 1364-1965mg/m(2) . No treatment related deaths occurred. These results support the thesis that aldoxorubicin can be administered safely and for prolonged periods with continuous infusion I-M and achieves high response rates and SD, with substantial tumor necrosis. Based on these results, the decision was made to stop further aldoxorubicin dose escalation and continue to enroll only in the 250mg/m(2) cohort.

Following conclusion of the poster presentation, a PDF copy of the poster will be available at http://cytrx.com/investors/presentations.

About Soft Tissue Sarcoma

Soft tissue sarcoma is a cancer occurring in muscle, fat, blood vessels, tendons, fibrous tissues and connective tissue. It can arise anywhere in the body at any age. STS remains a high unmet medical need because of the difficulty in treating the more than 50 types of this aggressive cancer. According to the American Cancer Society, in 2016 more than 12,300 new cases were diagnosed in the U.S. and approximately 5,000 Americans died from this disease. In addition, approximately 40,000 new cases and 13,000 deaths in the U.S. and Europe are part of a growing underserved market.

About Aldoxorubicin

Aldoxorubicin is a rationally-engineered cytotoxic which combines doxorubicin, a widely used chemotherapeutic agent, with a novel linker molecule that binds directly and specifically to circulating albumin, the most abundant protein in the bloodstream. Protein-hungry tumors concentrate albumin, which facilitates the delivery of the linker molecule with the attached doxorubicin to tumor sites. In the acidic environment of the tumor, but not the neutral environment of healthy tissues, doxorubicin is released. Typically, doxorubicin is delivered systemically and is highly toxic, which limits its dose to a level below its maximum therapeutic benefit. Doxorubicin also is associated with many side effects, especially the potential for damage to heart muscle at cumulative doses greater than 450 mg/m2. Using this acid-sensitive linker technology, aldoxorubicin delivers greater doses of doxorubicin (3 1/2 to 4 times). To date, there has been no evidence of clinically significant effects of aldoxorubicin on heart muscle, even at cumulative doses of drug well in excess of 6,500 mg/m2 of doxorubicin equivalents. Aldoxorubicin is the first-ever single agent to show superiority over doxorubicin in a randomized clinical trial in first-line STS.

About CytRx Corporation

(MORE TO FOLLOW) Dow Jones Newswires

May 17, 2017 17:04 ET (21:04 GMT)
I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 165

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 107

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading
Hagerty's Fifth Film Win Keeps Its Media Engine Humming

Updated Category News Views 67

A lap record, a camera crew, and five straight trophies make a louder statement than another glossy corporate slogan. Hagerty won Best Journalism Film at the 2026 International Motor Film Awards on Nov. 14, held at the Petersen Automotive Museum in Los Angeles. The company has taken that particular award home five years running, powered again by Jason Cammisa and his...

Continue Reading
Jumia’s Breakeven Retreat Invites Legal Scrutiny

Updated Category News Views 108

Jumia’s credibility problem did not arrive wearing a disguise. The company spent much of 2026 telling investors that a fourth-quarter Adjusted EBITDA breakeven was still on the table, then discarded that target after reporting third-quarter results. For holders of NYSE:JMIA, that kind of reversal stings because the promise was not some stray talking point; it was...

Continue Reading
Marina del Rey's Travel Award Brings Fresh Attention

Updated Category News Views 78

A harbor town just got handed a useful little megaphone. On November 18, 2026, the Marina del Rey Tourism Board said Marina del Rey had been selected as a winner in Good Housekeeping's 2027 Travel Awards. That is not a quarterly earnings event, and nobody ought to dress it up as one. Still, in the visitor economy, recognition from a broad consumer publication can matter...

Continue Reading
Nellie's 50% Booking Jump Reveals a Quieter Luxury

Updated Category News Views 124

Silicon Valley’s rich are apparently tired of performing wealth for strangers, and frankly, that tracks. Nellie’s 2027 forecast says its mostly tech-money clientele is moving past the old trophy case of private jets, famous resort towns, and suites priced like small houses. The prize now is privacy, a clean schedule, and somebody competent fixing the ugly little...

Continue Reading
Norfolk Southern's 200-Year Campaign Meets a Hard Market

Updated Category News Views 61

Two centuries of railroad history can stir the blood, but it does not move a single carload by itself. Norfolk Southern has opened its 200-year railroading celebration with the GeneratioNS campaign, a three-locomotive NS 200 commemorative series, and plans for public events across its network. For a railroad with deep roots and very modern operational pressures, this is...

Continue Reading
Sokin’s UAE License Turns Expansion Into Real Payments Plumbing

Updated Category News Views 118

Dubai expansion headlines are cheap; regulated local money movement is not. That is why Sokin’s newly approved Dubai Financial Services Authority license deserves more than the usual fintech applause line. The company has paired that approval with AED accounts, local payment rails, a One Za’abeel office and a plan to double its UAE staff over the next year. None of...

Continue Reading
Lithium's Next Leg Depends on Storage, Not EV Hype

Updated Category News Views 93

Grid batteries are quietly becoming lithium’s second engine, and that matters more than another flashy electric-vehicle sales headline. The market is projected to rise from $40.87 billion in 2026 to $57.77 billion by 2031, a 7.2% compound annual growth rate. Respectable growth, certainly. But this is not a straight line, and anybody treating a five-year market forecast...

Continue Reading
First US Extends Buyback Clock Through Year-End 2027

Updated Category News Views 123

A buyback extension is not a thunderclap; it is a bank board keeping a useful tool within reach. First US Bancshares has pushed the expiration of its existing repurchase authorization from December 31, 2026, to December 31, 2027. That matters, but investors ought to resist turning a calendar change into a grand earnings prophecy. The company has bought back 2,122,972...

Continue Reading

Top 5 Most Recently Viewed Articles

City National Rochdale Welcomes New Leadership with CEO Appointment

Updated Category News Views 270

New Leadership at City National Rochdale City National Rochdale, LLC is thrilled to announce the promotion of Gregg Giaquinto to the position of Chief Executive Officer. With over 25 years of experience in the financial services sector, Giaquinto is poised to lead the firm into its next chapter. Experience and Strategic Vision Giaquinto's journey with City National...

Continue Reading
Tesla's EV Deliveries Struggle Against Growing Competition

Updated Category News Views 119

Tesla's Challenges in EV Deliveries Tesla (NASDAQ: TSLA) delivered approximately 1.64 million electric vehicles in a recent year, falling behind competitors like BYD, which surpassed 2.2 million deliveries. This represents a second consecutive annual decline for Tesla, signifying growing challenges within its automotive sector. The significant drop in deliveries during...

Continue Reading
Greenwave Technology Solutions Boosts Rare-Earth Recycling Efforts

Updated Category News Views 208

Greenwave Technology Solutions Expands Rare-Earth Metal Recovery In light of recent supply chain challenges, Greenwave Technology Solutions, Inc. (NASDAQ: GWAV) is intensifying its initiatives to recover rare-earth metals from end-of-life products. With key minerals being restricted from export, such as gallium and germanium, the company's moves come at a crucial time,...

Continue Reading
Eyenovia Explores Strategic Opportunities with Chardan's Help

Updated Category News Views 267

Eyenovia Engages Chardan for Strategic Alternatives Review Recently, Eyenovia, Inc. (NASDAQ: EYEN), an innovative ophthalmic technology company, outlined its plans to evaluate various strategic opportunities. By partnering with Chardan, the company will assess a broad spectrum of options aimed at optimizing its business operations and future growth prospects. Advancements...

Continue Reading
Pandion Optimization Alliance: A Legacy of 100 Years Empowering Collaboration

Updated Category News Views 291

Pandion Optimization Alliance Celebrates 100 Years of Success This month marks a momentous occasion for Pandion Optimization Alliance as it celebrates a century of uniting organizations through collaboration and shared strength. What initiated as a small rural hospital project in 1925 has now transformed into a massive multi-billion-dollar marketplace. The vision of the...

Continue Reading